Genomics Reporting Implementation Guide, published by HL7 International / Clinical Genomics. This guide is not an authorized publication; it is the continuous build for version 3.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/genomics-reporting/ and changes regularly. See the Directory of published versions
Generated Narrative: Observation EGFR-L858R-therapuDrug2
status: Final
category: Laboratory, Genetics
code: Therapeutic Implication
effective: 2023-02-01
performer: Practitioner Test Dolin
derivedFrom: Observation Genetic variant assessment
component
code: Therapeutic Implication
value: Responsive
component
Related Artifact for Observation component: No display for RelatedArtifact (type: citation; url: https://www.jmdjournal.org/cms/attachment/ee43a71b-81de-4cb3-ac5e-2fb9a7d41491/gr2.jpg)
code: Level of evidence
value: Tier I - Level A
component
code: Associated phenotype
value: Non-small cell lung cancer
component
Related Artifact for Observation component: No display for RelatedArtifact (type: citation; url: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/types-treatment)
code: Medication assessed
value: Erlotinib
component
Related Artifact for Observation component: No display for RelatedArtifact (type: citation; url: https://civicdb.org/evidence/2994/summary)
code: Conclusion Text
value: Non-small cell lung cancer with EGFR L858R mutation is sensitive to erlotinib